Adia Nutrition Inc. Secures IRB Approval for Autism Clinical Study

ADIA NUTRITION INC +49.29% Pre

ADIA NUTRITION INC

ADIA

0.21

0.21

+49.29%

0.00% Pre

Adia Nutrition Inc. has received approval from the independent Institutional Review Board (IRB) BeyondBound for its clinical study protocol focused on Autism Spectrum Disorder (ASD). The approved study, led by Adia Med of Winter Park LLC, will enroll 100 children ages 3-12 to investigate the therapeutic benefits of combining glutathione with umbilical cord blood-derived stem cells compared to glutathione alone. The study has been submitted to ClinicalTrials.gov and is in final review before becoming publicly visible. No grant or funding from multiple organizations is mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 278050) on December 15, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.